Physician profile
Brian E Dubow
NPI 1225140569
$2,565.71
in general payments reported to CMS, 2019-2025
21 companies · $565 in 2025
The $565 reported for 2025 was less than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $158 · 2021: $285 · 2022: $421 · 2023: $438 · 2024: $281 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,284.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $424.71 | 2023-2025 | |
| Urovant Sciences INC | $275.44 | 2022 | |
| Amgen INC. | $209.97 | 2020-2023 | Otezla |
| Botanix Sb INC | $175.11 | 2025 | Sofdra |
| Sumitomo Pharma America, INC. | $165.47 | 2023 | Gemtesa |
| Sanara Medtech INC. | $155.71 | 2021 | |
| Galderma Laboratories, L.P. | $153.09 | 2019-2022 | |
| Allergan, INC. | $151.92 | 2019-2022 | |
| Celgene Corporation | $145.72 | 2019 | |
| Pfizer INC. | $141.96 | 2022-2025 | |
| Merz North America, INC. | $76.49 | 2021-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $75.31 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $68.98 | 2019-2022 | |
| Epi Health, LLC | $65.13 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $55.22 | 2025 | Oxistat, Purified Cortrophin Gel |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $54.08 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $53.63 | 2019-2021 | |
| Organon LLC | $47.07 | 2025 | Vtama |
| Regeneron Healthcare Solutions, INC. | $26.05 | 2023 | Libtayo |
| Arcutis Biotherapeutics, INC. | $22.75 | 2024 | Zoryve |
| Lnhc, INC | $21.90 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Dubow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.